| Budget Amount *help |
¥44,070,000 (Direct Cost: ¥33,900,000、Indirect Cost: ¥10,170,000)
Fiscal Year 2021: ¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
Fiscal Year 2020: ¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
Fiscal Year 2019: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
Fiscal Year 2018: ¥12,350,000 (Direct Cost: ¥9,500,000、Indirect Cost: ¥2,850,000)
|
|---|
| Outline of Final Research Achievements |
We aimed to realize a novel cancer therapy by targeting specific glycan structures (Htype3) covering the outermost layer of pancreatic cancer cells with BC2 lectin. LDC, which is BC2 lectin conjugated with Pseudomonas aeruginosa exotoxin, showed high antitumor effect not only on pancreatic cancer but also on colon cancer and stomach cancer. Aiming for clinical application to humans, we purified a GMP-grade formulation in collaboration with a pharmaceutical company to obtain a pure trimeric LDC, but gave up the development of human application due to its strong off-target accumulation and toxicity in the kidney and liver. On the other hand, we found that the carrier protein of Htype3 on the surface of cancer cells is CEA and that BC2 lectin can be used as a modification of doxorubicin to improve its targetability and as a carrier of photoimmunomaterials, opening a new path for the clinical application of BC2 lectin.
|
